







Vol.1 , No. 3, Publication Date: Jun. 11, 2015, Page: 56-69
[1] | Azza A. Kamel, Chemical Industries Division, National Research Centre (NRC), Dokki, Cairo, Egypt. |
Phosphorus compounds in general and phosphonates in particular, are a corner stone in pharmaceutical drugs. Many of these compounds exhibit antifungal, antibacterial, anticancer and significant analgesic/antiinflammatory properties. Bisphosphonates and aminophosphonates, taken as representative examples, are important precursors of the corresponding bisphosphonic acid with, in many cases, remarkable pharmacologically interesting properties. The benefits of these compounds use in the prevention of bone mass loss in addition to their antitumor potential when used in the adjuvant setting were approved in many literatures. This article aims to shed light on phosphorus compounds as rising stars in pharmaceutical drugs in addition to their increasing role as antioxidants and antidiabetics. The available body of clinical trials supporting the use of these compounds in this setting was briefly scrutinized. These results recommended for a careful consideration of the role that phosphorus compounds can act as a new generation of antioxidants and antidiabetics. The emphasis is on the recent information added to this topic. Although the author has attempted the review to be encyclopedic with respect to the topics, the article is not exhaustive.
Keywords
Phosphorus Compounds, Bisphosphonates, Aminophosphonates, Antioxidants, Antidiabetics
Reference
[01] | Mader, M. M., Bartlett P. A., Chem. Rev., 1997, 97, 1281-1301. |
[02] | Holla, B. S., Ashok, M., Phosphorus, Sulfur, Silicon, and Relat. Elem. 2007,182, 981-991. |
[03] | Bul, E. O. J., Naidu, M. S. R., Phosphorus, Sulfur, Silicon, and Relat. Elem., 2000,162, 231-243. |
[04] | Gilard, V., Martino, R., Malet-Martino, M., Niemeyer, U., Pohl, J., J. Med. Chem., 1999, 42, 2542-2560. |
[05] | Maier, L., Diel, P. J., Phosphorous Sulphur and Silicon, 1991, 57, 57-64. |
[06] | Leon, A., Liu, L., Yang, Y., Hudock, M. P., Hall, P., Yin, F., Studer, D., Puan, K. J., Morita, C. T., Oldfield, E., J. Med. Chem., 2006, 49, 7331-7341. |
[07] | Kafarski, P., Lejczak, B., Curr. Med. Chem. Anticancer Agents, 2001, 1, 301-312. |
[08] | Gouverneur, V., Lalloz, M. N., Tetrahedron Lett., 1996, 37, 6331-6334. |
[09] | Yoneda, T., Sasaki, A., Dustan, C., William, P. J., Bauss, F., De Clerck, Y. A., Mundy, G. R., J. Clin. Invest., 1997, 99, 2509-2517. |
[10] | Ross, J. R., Saunders, Y., Edmonds, P. M., BMJ, 2003, 327, 469-474. |
[11] | Tim, V. W., Manon, T. H., Eric, F., Jan, B. V., The Oncologist, 2009, 14, 181-191. |
[12] | Sanders, J. M., Ghosh, S., Chan, J. M., Meints, G., Wang, H., Raker, A., J. Med Chem., 2004, 47, 375-384. |
[13] | Thompson, K., Rogers, M. J., J. Bone Miner Res., 2004, 19, 278-288. |
[14] | Graham, R., Russell, G., Bone, 2011, 49, 2-19. |
[15] | Waldmann, H., Bialy, L., Angew. Chem., 2005, 44, 3814-3819. |
[16] | Gautier, A., Garipova, G., Salcedo, C., Balieu, S., Piettre, S. R., Angew. Chem. Int. Ed., 2004, 43, 5963-5967. |
[17] | Drake, M. T., Cremers, S. C., Mol. Interv., 2010, 10,141-152. |
[18] | Martin, T. J., Grill, V., Australian Prescriber, 2000, 23, 130-132. |
[19] | Fernandes, C., Leite, R., Rodrigo, S., Lancas, F. M., Quimica Nova, 2005, 28, 274-280, Chem. Abstr. 2005, 142, 366626. |
[20] | Papapoulos, S. E., Nature Reviews Rheumatology, 2013, 9, 263-264. |
[21] | Boikos, S. A., Hammers, H. J., Journal of Clinical Oncology (JCO), 2012, 30, e299. |
[22] | Saunders, Y., Palliat Med., 2004, 18, 418-431. |
[23] | Hung, S. H., Tsai, W. Y., Tsao, P. N., Chou, H. C., Hsieh, W. S., Journal of the Formosan Medical Association, 2003, 102, 801-804. |
[24] | Graham R., Russell G., Bone, 2011, 49, 2-19. |
[25] | McClung M. R., J. Clin. Densitom., 2010, 13, 132. |
[26] | Reid I. R., Brown J. P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U. N., Engl. J. Med., 2002, 346, 653-661 |
[27] | van-Beek, E., Löwik, C., van der Pluijm, G., Papapoulos, S., J. Bone Miner. Res., 1999, 14, 722–729. |
[28] | Clézardin, P., Ebetino, F. H., Fournier, P. G., Cancer Res., 2005, 65, 4971-4974. |
[29] | Abdou, W. M., Ganoub, N. A., Fahmy, A. F. M., Shaddy, A. A., Monatsh. Chem. 2006, 136, 105-116. |
[30] | Abdou, W. M., Khidre, R. E., Kamel, A. A., Arch. Pharm. Chem. Life Sci., 2012, 345, 123-136. |
[31] | Abdou, W. M., Khidre, M. D., Sediek, A. A., The design and synthesis of sulfur and nitrogen containing bisphosphonic acids and their role in oncology in: The chemistry and biologically activity of synthetic and natural compounds, modern aspects of chemistry of heterocycles,Russian Academy of Natural Science, Kartsev, V. G. (ed.).2010, pp. 209-212. |
[32] | Abdou, W. M., Shaddy, A. A., J. Med. Chem. Res., 2010, 19, 39-40. |
[33] | Abdou, W. M., Khidre, R. E., Shaddy, A. A., J. Heterocyclic Chem., 2013, 50, 33-41. |
[34] | Abdou, W. M., Kamel, A. A., Shaddy, A. A., Eur. J. Med. Chem., 2010, 45, 5217-5224. |
[35] | Abdou, W. M., Shaddy, A. A., Arkivoc, 2009, 14,143-182. |
[36] | Abdou, W. M., Ganoub, N. A., EL-Khoshnieh, Y. O., Synlett, 2003, 785-790. |
[37] | Prasad, G. S., Rao, G. N., Journal of Modern Medicinal Chemistry, 2013, 1, 49-60. |
[38] | Moonen, K., Laureyn, I., Stevens, C. V., Chem Rev, 2004, 104, 6177-6185 |
[39] | Laureyn, I., Stevens, C. V., Soroka, M., Malyse, P., Arkivoc, 2003, 6, 102-115. |
[40] | Kafarski, P., Lejczak, B., Current Medicinal Chemistry - Anti-Cancer Agents, 2001, 1, 301-312. |
[41] | Abdel-Monem, W. R., Eur. J. Chem., 2010, 1, 168-172. |
[42] | Schug, K. A., Lindner, W., Chem. Rev. 2005, 105, 67-114. |
[43] | Wrobleski, S. T., Lin, S., Hynes, J. Jr., Wu, H., Pitt, S., Bioorg. Med. Chem. Lett., 2008, 18, 2739-2744. |
[44] | Prasad, G. S., Rao, G. N., Journal of Modern Medicinal Chemistry, 2013, 1, 49-60. |
[45] | Chandrasekhar, S., Narsihmulu, Ch., Shameen, S. S., Saritha, B., Jayaprakash, S., Synlett, 2003, 505-506. |
[46] | Takahashi, H., Yoshioka, M., Imai, N., Onimura, K., Kobayashi, S., Synthesis, 1994, 8, 763-764. |
[47] | Heydari, A., Karimian, A., Ipaktschi, J., Tetrahedron Lett, 1998, 39, 6729-6732. |
[48] | Azizi, N., Saidi, M. R. Eur. J. Org. Chem., 2003, 46, 30-33. |
[49] | Lee S., Park J. H., Kang J, Lee J. K., J., Chem.Soc. Chem.Commun., 2001, 1698-1699. |
[50] | Akiyama, T., Sanada, M., Fuchibe, K., Synlett, 2003, 1463-1464. |
[51] | Abdou, W. M., Barghash, R. F., Bekhiet, M. S., RSC Org. Advances, 2013, 1528-1540. |
[52] | Shaddy, A. A., Kamel, A. A., Abdou, W. M., Synth. Commun., 2013, 43, 236-252. |
[53] | Abdou, W. M., Barghash, R. F., Sediek, A. A., Eur. J. Med. Chem., 2012, 57, 362-372. |
[54] | Abdou, W. M., Barghash, R. F., Bekheit, M. S., Arch. Pharm. Chem. Life Sci. 2012, 345, 884-895. |
[55] | Kamel, A. A., Geronikaki, A., Abdou, W. M., Eur. J. Med. Chem. 2012, 51, 239-249 |
[56] | Abdou, W. M., Kamel, A. A., Khidre, R. E., Geronikaki, A., Ekonomopoulou, M. T., Chem. Biol. & Drug Des., 2012, 79, 719-730. |
[57] | Abdou, W. M., Barghash, R. F., Khidre, R. E., Monatsh. Chem., 2013, 144, 1233-1242. |
[58] | Hirschmann, R., Smidt, A. B., Taylor, C. M., Benkovic, P. A., Taylor, S. D., Yager, K. M., Sprengeler, P. A., Benkovic, S. J., Science, 1994, 265, 234-237. |
[59] | Meyer, F., Laaziri, A., Papini, A. M., Uziel, J., Juge, S., Tetrahedron, 2004, 60, 3593-3597. |
[60] | Smith, W. W., Bartlett, P. A., J. Am. Chem. Soc., 1998, 120, 4622-4628. |
[61] | For examples and applications of different naturally occurring β-aminophophonates/ phosphonic acids see, e.g.: Aminophosphonic and aminophosphinic acids, chemistry and biological activity, ed. V. P. Kukhar, H. R. Hudson, John Wiley and Sons, NY, 2000. |
[62] | He, X. P., Xie, J., Tang, Y., Li, J., Chen, G. R., Curr. Med. Chem., 2012, 19, 2399-2405. |
[63] | Butnariu, M., Grozea, I., J. Bioequiv. Availab., 2012, 4, xvii-xix. |
[64] | Sugioka, K., Shimosegawa, Y., Nakano, M., FEBS Letters, 1987, 210, 37-90. |
[65] | Pacheco, J., Gonsebatt, M., Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 2009, 674, 137–147. |
[66] | Evans, P., Halliwell, B., British Journal of Nutrition, 2001, 85, 67S-74S. |
[67] | Potenza, N., Papa, U., Russo, A., Cell Biol. Int., 2009, 33, 734-738. |
[68] | Aruoma, O. I., Journal of the American Oil Chemists' Society, 1998, 75, 199-212. |
[69] | Apel, K., Hir, H., Annual Review of Plant Biology, 2004, 55, 373-399. |
[70] | Catalá, A., The International Journal of Biochemistry & Cell Biology, 2006, 38, 1482–1495. |
[71] | Nurulain, S. M., Szegi, P., Tekes, K., Naqvi S. N., 2013, 64, 169-177. |
[72] | Schwetlick, K., Pionteck, J., Habicher, T. W. D., Eur. Polymer J. 1987, 23, 383-388. |
[73] | Földes, E., Maloschik, E.,Kriston, I., Staniek, P., Pukánszky, B., Polymer Degradation and Stability, 2006, 91,479–487. |
[74] | Schwetlick, K., In mechanism of polymer of degradation and stabillisation, ed. Elsevier Applied Science, London and New York, 1990. |
[75] | Hall, G. H., Neal, M. A., Jenkins, S. D., Siddiqui, J. A., US6827897 B2, 2004, US 09/818,334. |
[76] | Vulic, I.,Vitarelli,G.,Zenner, J. M., Polymer Degradation and Stability, 2002,78, 27–34. |
[77] | Schwetlick, K., Habicher, W. D., Die Angewandte Makromolekulare Chemie, 1995, 232, 239–246. |
[78] | Habiche, W. D., Bauer, I., Pospíšil, J., Macromolecular Symposia, 2005, 225, 147–164. |
[79] | Lester, P. J., Burton, US 4912155 A, 1987. |
[80] | Schwetlick, K., König, T., Rüger, C.,Pionteck, J., Habicher, W. D., Polymer Degradation and Stability, 1986, 15, 97–108. |
[81] | Schwetlick, K., Pionteck, J., Winkler, A., Hfihner, U., Kroschwitz, H., Habicher, W. D., Polymer Degradation and Stability, 1991, 31, 219-228. |
[82] | Ahmed, O. M., Hussein, A. M., Ahmed, R. R., Med.Chem., 2012, 2, 20-28. |
[83] | De la Cruz, J. P., Carrasco, T., Ortega, G., Sanchez, C. F., Lipids, 1992, 27, 192-194. |
[84] | Kamel, A. A., Khidre, M. D., Abdou, W. M., Heterocyclic Chemistry, accepted for publications, 2014, DOI 1002/jhet.2260, Published online 00 Month 2014 in Wiley Online Library (wileyonlinelibrary.com). |
[85] | Abdou, W. M., Ganoub, N. A., Barghash, R. F., Synthetic Communications, 2014, 44, 2669-2678. |
[86] | Rosenbloom, A. L., Joe, J. R., Young, R. S., Winter, W. E., Diabetes Care, 1999, 22, 345-354. |
[87] | Kamaeswara, B. R., Giri, R., Kesavulu, M. M., Apparao, C. H, J. Ethnopharmacol., 2001, 74, 69-74. |
[88] | Zimmet, P., Alberti, K. G., Shaw, J., Nature, 2001, 414, 782-787. |
[89] | Caro, J. F., Triester, S., Patel, V. K., Tapscott, E. B., Frazier, N. L., Dohm, G. L., Hormone and Metabolic Research, 1995, 27, 19-22. |
[90] | Stride, A., Shields, B., Gill-Carey, O., Chakera, A. J., Colclough, K., Ellard, S., Hattersley, A. T., Diabetologia, 2014, 57, 54-56. |
[91] | Gloyn, A. L., Hum. Mutat., 2003, 22, 353-362. |
[92] | Gloyn, A. L., Front diabetes, in Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics, Matschinsky, F. M., Magnuson, M. A. (eds.), 16, pp 92-109, Karger, Basel, 2004. |
[93] | Abdul-Ghani, M. A., DeFronzo, R. A., Endocr. Pract., 2008, 14, 782-790. |
[94] | Agius, L., Biochem., 2008,414, 1-18. |
[95] | Takagi C, Bursell S. E., Lin Y. W., Takagi H., Duh E., Jiang Z., Clermont A. C., King G. L., Invest. Ophthalmol. Vis. Sci., 1996, 37, 2504-2518. |
[96] | Deacon, C. F., Carr, R. D., Holst, J. J., Frontiers in Bioscience, 2008, 13, 1780-1794. |
[97] | Verspohl E. J., Pharmacol. Ther., 2009, 124, 113-138. |
[98] | Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M., Diabetes Care, 2009, 32, 1880- 1886. |
[99] | Trujillo, J. M., Nuffer, W., Ann Pharmacother., 2014, 48, 1494-1501. |
[100] | Yabe, D. , Kuwata, H., Usui, R. , Kurose, T. , and Seino, Y., Current Medical Research & Opinion. Informa Healthcare, Posted online on May 20, 2015 (doi:1185/030079201045471). |
[101] | Priyadarsini, R. L., Namratha, J. R., Reddy, D. R., International Journal of Pharmacy and Pharmaceutical Sciences, 2012, 4, 81-87. |
[102] | Pal, M., Curr. Med. Chem., 2009, 16, 3858-3874. |
[103] | Bae, J., Kim, T., Kim M., Park, J., Ahn, Y., Sensors, 2010, 10, 5031-5053. |
[104] | Matschinsky, F. M., Nat. Rev. Drug Discov., 2009, 8, 399-416. |
[105] | Matschinsky, F. M., Diabetes, 2002, 51, S394-S404. |
[106] | Verspohl, E. J., Pharmacological Reviews, 2012, 64, 188-237. |
[107] | Grimsby, J., Matschinsky, F. M., Grippo, J. F., Discovery and actions of glucokinase activators, in Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics, Matschinksy, F. M., Magnuson, M. A. (eds), 16, pp 360-378, Karger, Basel, 2004. |
[108] | Sarabu, R., Berthel, S. J., Kester, R. F., Tilley, J. W., Expert Opin. Ther. Pat, 2008, 18, 759-768. |
[109] | Grimsby, J., Berthel, S. J., Sarabu, R., Curr. Top. Med. Chem., 2008, 8, 1524-1532. |
[110] | Dunten, P., Swain, A., Kammlot, U., Crowther, R., Lukacs, C. M., Levin, W., Reik, L., Grimsby, J., Corbett, W. L., Magnuson, M. A., Matschinsky, F. M., Grippo, J. F., Crystal structure of human liver glucokinase bound to a small molecule allosteric activator. Insights into the activating mutations, in Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics Front Diabetes, Matschinsky, F. M., Magnuson, M. A. (eds.), 16, pp 145-154, Karger, Basel, 2004. |
[111] | Kamata, K., Mitsuya, M., Nishimura, T., Eiki, J., Nagata, Y., Structure, 2004, 12, 429-438. |
[112] | Gnudi, L., Gruden, G., Viberti, G., Pathogenesis of diabetic nephropathy, in Textbook of Diabetes, Pickup, J. C., Williams, G. (eds.), pp 1-21, Blackwell Science, Oxford, 2003. |
[113] | Conway, B. R., Maxwell, A. P., Nephron., 2009, 112, 213-221. |
[114] | Obrosova, I. G., Neurotherapeutics, 2009, 6, 638-647. |
[115] | Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G., Brett, C. M., Giacomini, K. M. J., Clin. Invest. 2007, 117, 1422-1431. |
[116] | Chatterjee, A. K., Kaveeshwar, U., Defence Science Journal, 1991, 41, 143-147. |
[117] | Al-Ghanim, K. A., Scientific Research and Essays, 2012, 7, 1674-1680. |
[118] | Lakshmanan, S., Rajendran, A., Sivasubramaniyan, C., International Journal of Research in Biological Sciences, 2013, 3, 34-38. |
[119] | Kavalali, G. H., Tuncel, S., Goksel, H. H., Hatemi, J., Ethnopharmacol., 2002, 84, 241-245. |